CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,716 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01298648
NCT01298648N/ACompleted

Special Investigation (All Cases Investigation in Patients With Crohn's Disease)

AbbVie (prior sponsor, Abbott)·observational·Posted Feb 18, 2011·Updated Jul 2, 2018

In Brief

An observational study for Crohn's Disease. Completed, enrolled 1,716 participants across 1,131 sites.

Detailed Summary

This study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of Humira for the treatment of Crohn's disease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2011
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.4 years ago